- Halaven (eribulin mesylate); Eisai; For the treatment of metastatic breast cancer, Approved November 2010
- Herceptin (trastuzumab); Genentech; For the treatment of gastric cancer, Approved October 2010
- Jevtana (cabazitaxel); sanofi aventis; For the treatment of prostate cancer, Approved June 2010
- Provenge (sipuleucel-T); Dendreon; For the treatment of hormone refractory prostate cancer, Approved May 2010
- Xgeva (denosumab); Amgen; For the prevention of skeletal-related events in patients with bone metastases from solid tumors, Approved November 2010
- Zuplenz (ondansetron oral soluble film); Strativa Pharmaceuticals; For the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting, Approved July 2010
So what will 2011 look like in oncology? I'm sure we'll see several new targeted therapies, vaccines and other novel drugs used to treat and prevent cancer. It should get more interesting as we get more involved with genomics and personalized medicine in the area of oncology.